Research & Development
Policy & Regulation
Trends & Finance
Stock: Page 2
LumiraDx Q2 revenues down 49% on drop in COVID testing
For the second quarter ended June 30, the London-based firm posted revenues of $44.7 million, compared to revenues of $87.2 million in Q2 2021, short of Wall Street analysts' average estimate of $53.1 million.
August 17, 2022
Agilent Technologies Q3 revenues rise 8%
For the fiscal third quarter ended July 31, Agilent's Life Sciences and Applied Markets Group posted revenues of $1.02 billion, a year-over-year increase of 14%; the CrossLab Group posted revenues of $359 million, a year-over-year increase of 5%; and the Diagnostics and Genomics Group posted revenues of $340 million, a year-over-year decrease of 2%.
August 16, 2022
Sophia Genetics revenues up 15% on platform volumes
The firm said that its year-over-year revenue growth on a constant currency basis, excluding COVID-19-related revenues, was 36%.
August 8, 2022
VolitionRx prices $6M public offering
The company said that gross proceeds to Volition from the offering are expected to be $6 million. Volition also granted the underwriter a 30-day option to purchase up to an additional 450,000 shares of its common stock at the public offering price. The offering is expected to close on or about August 2.
July 28, 2022
LumiraDx prices $75.3M public offering
Before deducting underwriting discounts and commissions and other offering expenses, the gross proceeds from the offering are expected to be approximately $75.3 million. The offering is expected to close on July 25.
July 20, 2022
Danaher Q2 diagnostics revenues rise 9%
For the quarter ended July 1, the company said its overall revenues, including revenues for its diagnostics, life sciences, and environmental and applied solutions divisions, rose 7% year-over-year to $7.75 billion from $7.22 billion, well ahead of Wall Street analysts' average estimate of $7.3 billion.
July 20, 2022
Quest Diagnostics Q4 revenues down 15% on COVID testing but base business grew
In pilot study, liquid biopsy test differentiates between localized and metastatic cancer to inform tailored treatment
SD Biosensor, SJL Partners complete acquisition of Meridian Bioscience
Roche reports flat diagnostics revenue growth for 2022
French point-of-care testing firm Biosynex to acquire Chembio Diagnostics for $17.2M
Sherlock Biosciences acquires Sense Biodetection to drive CRISPR-based test adoption
LumiraDx announces proposed share offering
The London-based firm also intends to grant underwriters a 30-day option to purchase up to an additional six million common shares at the public offering price.
July 18, 2022
Centogene Q1 year-over-year revenues rise 3%
The Rostock, Germany-based firm posted Q1 diagnostics segment revenues of 7.1 million euros, up 11% compared to 6.4 million euros in the prior year's corresponding quarter. The increase in diagnostic segment revenues was mainly due to an 18% year-over-year revenue rise for whole exome sequencing and whole genome sequencing, the firm said.
July 14, 2022
Quotient discloses underwritten public offering price
The company said the aggregate net proceeds to Quotient from this offering are expected to be approximately $18.5 million. The company also offered all of the securities sold. Furthermore, Quotient granted the underwriters a 30-day option to purchase up to an additional 10,000,000 of its ordinary shares. The company said that it plans to use net proceeds to fund the ongoing development and commercialization of its MosaiQ microarray menu. It added that funds will go toward working capital, operating expenses, and other general corporate purposes.
June 23, 2022
Sophia names Ken Freedman as chief revenue officer
Previously, Freedman was executive vice president of sales for Naviga, where he grew revenue streams, built processes, and helped customers from Canada to Latin America find success, the company said.
January 26, 2022
Lucid closes Nasdaq initial public offering
It closed 5 million shares of common stock at a price to the public of $14 per share for total gross proceeds of $70 million before deducting underwriting discounts and commissions and estimated offering expenses.
October 19, 2021
Lucid Diagnostics files for IPO on Nasdaq exchange
The number of shares to be offered and the price range for the offering have not yet been determined. Lucid is a majority-owned subsidiary of interventional medical device developer PAVmed.
September 22, 2021
Page 2 of 3